Johnson & Johnson (NYSE:JNJ) Stake Raised by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,387,671 shares of the company’s stock after acquiring an additional 100,936 shares during the quarter. Johnson & Johnson makes up 0.8% of Vanguard Group Inc.’s investment portfolio, making the stock its 16th largest holding. Vanguard Group Inc. owned 9.52% of Johnson & Johnson worth $35,954,223,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $4,071,642,000. Wellington Management Group LLP raised its stake in shares of Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after purchasing an additional 3,391,657 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 7,875.8% during the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after buying an additional 2,064,175 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $193,050,000. Finally, abrdn plc increased its holdings in Johnson & Johnson by 104.1% in the fourth quarter. abrdn plc now owns 2,014,743 shares of the company’s stock worth $315,791,000 after buying an additional 1,027,441 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.3 %

Shares of JNJ stock opened at $145.97 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm has a fifty day moving average of $148.27 and a 200-day moving average of $154.65. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The stock has a market cap of $351.30 billion, a price-to-earnings ratio of 9.10, a P/E/G ratio of 2.42 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter last year, the company earned $2.68 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.40%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analysts Set New Price Targets

Several analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Monday. Bank of America lowered their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. The Goldman Sachs Group initiated coverage on Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 10th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Hold” and an average target price of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.